GAUSH MEDITECH LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.88 HKD | +1.95% |
|
-3.50% | -47.41% |
| May. 02 | Gaush Meditech Swings to Profit in 2023 | MT |
| Apr. 23 | Gaush Meditech Ltd Announces Change in Joint Company Secretary | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -47.41% | 369M | - | ||
| -3.17% | 9.39B | B+ | ||
| +1.62% | 1.45B | D | ||
| -3.32% | 1.43B | B+ | ||
| -6.75% | 1.21B | - | ||
| -14.59% | 899M | - | - | |
| +2.25% | 480M | - | ||
| +3.85% | 440M | - | - | |
| -19.75% | 356M | - | - | |
| -2.68% | 213M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2407 Stock
- Ratings Gaush Meditech Ltd